January 9, 2023
Via: PharmaphorumSupported by voting agreements from leading Amryt shareholders and directors, and unanimously approved and recommended by the boards of both companies, the total transaction is worth up to $1.48 billion, with upfront consideration of $1.25 billion representing a 107% premium […]
Industry, Mergers and Acquisitions, Pharma
December 28, 2022
Via: PharmaphorumIn pharma, multi-billion-dollar deals dominate M&A headlines, but most deals are far shorter of this range and generally lie between $10-$500 million. Since the first wave of consolidation started in 1988, there has been a significant concentration of the pharma […]
Cell and Gene Therapy, Clinical Trials, Industry, Research and Development
December 9, 2022
Via: Biopharma DiveGilead placed a major bet on cell therapy with its $12 billion acquisition of Kite in 2017. To the frustration of some investors, the business took several years to ramp up. But sales have substantially grown in recent months. Gilead’s […]
Cell and Gene Therapy, Industry, Mergers and Acquisitions
November 30, 2022
Via: GENAstraZeneca has agreed to acquire Neogene Therapeutics for up to $320 million cash, the companies said Tuesday, in a deal intended to bolster the buyer’s portfolio of cancer-fighting cell therapies. Neogene specializes in discovering, developing, and manufacturing next-generation T-cell receptor […]
August 19, 2020
Via: Contract PharmaJohnson & Johnson has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. for approximately $6.5 billion in cash. This acquisition expands Janssen Pharmaceutical’s portfolio in immune-mediated diseases into autoantibody-driven disease. J&J gains global rights to nipocalimab (M281), a […]
March 30, 2023
March 28, 2023
March 23, 2023
March 16, 2023
Copyright © 2023. All rights reserved
